Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis

키워드

참고문헌 (40)

1. Bartlett JG, "Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis", Gastroenterology, 75, pp.778~782 (1978)
2. Lessa FC, "Burden of Clostridium difficile infection in the United States", N Engl J Med, 372, pp.825~834 (2015)
3. McFarland LV, "Nosocomial acquisition of Clostridium difficile infection", N Engl J Med, 320, pp.204~210 (1989)
4. Samore MH, "Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea", Am J Med, 100, pp.32~40 (1996)
5. Shah S, "Gastric acid suppression does not promote clostridial diarrhoea in the elderly", QJM, 93, pp.175~181 (2000)
6. Muto CA, "A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use", Infect Control Hosp Epidemiol, 26, pp.273~280 (2005)
7. Kazakova SV, "A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile", Arch Intern Med, 166, pp.2518~2524 (2006)
8. Jayatilaka S, "Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors", Ann Clin Lab Sci, 37, pp.241~247 (2007)
9. Dubberke ER, "Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease", Arch Intern Med, 167, pp.1092~1097 (2007)
10. Aseeri M, "Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients", Am J Gastroenterol, 103, pp.2308~2313 (2008)
11. Howell MD, "Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection", Arch Intern Med, 170, pp.784~790 (2010)
12. Loo VG, "Host and pathogen factors for Clostridium difficile infection and colonization", N Engl J Med, 365, pp.1693~1703 (2011)
13. Stevens V, "Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure", Pharmacoepidemiol Drug Saf, 20, pp.1035~1042 (2011)
14. Barletta JF, "Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection", Mayo Clin Proc, 88, pp.1085~1090 (2013)
15. Barletta JF, "Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients", Crit Care, 18, pp.714~ (2014)
16. Youngouk Ro, "Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients", Gut and Liver, 10(4), pp.581~586 (2016), 거트앤리버 발행위원회
17. Thorens J, "Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study", Gut, 39, pp.54~59 (1996)
18. "Drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs)" (2016)[URL]
19. Tleyjeh IM, "Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis", PLoS One, 7, pp.e50836~ (2012)
20. Kwok CS, "Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis", Am J Gastroenterol, 107, pp.1011~1019 (2012)
21. Janarthanan S, "Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis", Am J Gastroenterol, 107, pp.1001~1010 (2012)
22. Deshpande A, "Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis", Clin Gastroenterol Hepatol, 10, pp.225~233 (2012)
23. MacLaren R, "Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit", JAMA Intern Med, 174, pp.564~574 (2014)
24. Moher D, "PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement", Ann Intern Med, 151, pp.264~269 (2009)
25. Guyatt GH, "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)
26. Guyatt GH, "GRADE guidelines 6. Rating the quality of evidence: imprecision", J Clin Epidemiol, 64, pp.1283~1293 (2011)
27. "GRADEpro" (2015)[URL]
28. DerSimonian R, "Meta-analysis in clinical trials", Control Clin Trials, 7, pp.177~188 (1986)
29. ASHP therapeutic guidelines on stress ulcer prophylaxis, "ASHP Commission on Therapeutics and approved by the ASHP board of directors on November 14, 1998", Am J Health Syst Pharm, 56, pp.347~379 (1998)
30. "Practice management guidelines for stress ulcer prophylaxis: EAST Practice Management Guidelines Committee" (2008)[URL]
31. Cook DJ, "The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients", Crit Care, 5, pp.368~375 (2001)
32. Grube RR, "Stress ulcer prophylaxis in hospitalized patients not in intensive care units", Am J Health Syst Pharm, 64, pp.1396~1400 (2007)
33. Choudhry MN, "Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease", QJM, 101, pp.445~448 (2008)
34. Alhazzani W, "Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis", Crit Care Med, 41, pp.693~705 (2013)
35. Barkun AN, "Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists", Value Health, 16, pp.14~22 (2013)
36. Harris RA, "Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis", Am J Gastroenterol, 92, pp.2179~2187 (1997)
37. Dubberke ER, "Burden of Clostridium difficile on the healthcare system", Clin Infect Dis, 55(Suppl 2), pp.S88~S92 (2012)
38. Olsen MA, "The burden of Clostridium difficile infection: estimates of the incidence of CDI from U.S. administrative databases", BMC Infect Dis, 16, pp.177~ (2016)
39. Al-Tureihi FI, "Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients", J Am Med Dir Assoc, 6, pp.105~108 (2005)
40. Dubberke ER, "Identification of medicare recipients at highest risk for Clostridium difficile infection in the US by population attributable risk analysis", PLoS One, 11, pp.e0146822~ (2016)

관련 논문AI추천